Intiflo 0.75mg/100ml Injection

Intiflo 0.75mg/100ml Injection belongs to the group of medicines called 'antiplatelet agents' used to prevent the formation of blood clots, thereby reducing the chance of Myocardial infarction. Intiflo 0.75mg/100ml Injection is used in the treatment of Acute coronary syndrome (ACS) in both patients who need to be managed medically and also people undergoing percutaneous coronary intervention (PCI) procedures. ACS is defined as a group of serious cardiac conditions wherein the blood flow to the heart decreases due to plaque formation. Intiflo 0.75mg/100ml Injection is also used in the treatment of patients undergoing urgent PCI procedures and also in patients undergoing intracoronary stenting.

Intiflo 0.75mg/100ml Injection contains Eptifibatide, which belongs to the monoclonal anti-glycoprotein IIb/IIIa receptor antibodies class. It works by blocking the glycoprotein IIb/IIIa receptor's activity, thereby preventing platelet aggregation. This causes inhibition of fibrinogen binding, reducing the chance of blood clot formation. Intiflo 0.75mg/100ml Injection reduces the risk of cardiovascular events like myocardial infarction (heart attack).

Intiflo 0.75mg/100ml Injection may cause certain side effects, such as bleeding, nausea, headache, abdominal pain, hypotension, vomiting, dizziness, decreased platelet count, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare professional will administer Intiflo 0.75mg/100ml Injection. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Intiflo 0.75mg/100ml Injection should be avoided if you are allergic to it. It is contraindicated in patients who have active internal bleeding, history of bleeding diathesis within 30 days, thrombocytopenia, severe uncontrolled hypertension, had recent major surgery or trauma, renal failure, using another glycoprotein IIb/IIIa inhibitor, a history of cerebrovascular accident within the last two years, or recent gastrointestinal or genitourinary bleeding, intracranial neoplasm, aneurysm, as it can cause serious adverse effects. Intiflo 0.75mg/100ml Injection is known to cause bleeding problems. If you observe severe bleeding that cannot be controlled, it is advised to stop administering Intiflo 0.75mg/100ml Injection immediately. Hence, close monitoring is needed for any bleeding conditions. Talk to your doctor before receiving Intiflo 0.75mg/100ml Injection if you had a recent severe injury or surgery due to the risk of severe bleeding problems. If you are pregnant, planning to become pregnant, or breastfeeding, inform your doctor before taking Intiflo 0.75mg/100ml Injection. Intiflo 0.75mg/100ml Injection is not recommended for children below 12 years of age as efficacy and safety have not been established.

Intiflo 0.75mg/100ml Injection contains Eptifibatide, which belongs to the monoclonal anti-glycoprotein IIb/IIIa receptor antibodies class. It works by blocking the glycoprotein IIb/IIIa receptor's activity, thereby preventing platelet aggregation. This causes inhibition of fibrinogen binding, reducing the chance of blood clot formation. Intiflo 0.75mg/100ml Injection results in reducing the risk of cardiovascular events like myocardial infarction (heart attack) and other cardiac events.

• Bleeding
• Nausea
• Headache
• Abdominal pain
• Hypotension
• Vomiting
• Dizziness
• Low platelet count
• Pain at the site of injection

Do not receive Intiflo 0.75mg/100ml Injection if you are allergic to it. It is contraindicated in patients who have active internal bleeding, history of bleeding diathesis within 30 days, thrombocytopenia, severe uncontrolled hypertension, had recent major surgery or trauma, renal failure, using another glycoprotein IIb/IIIa inhibitor, a history of cerebrovascular accident within the last two years, or recent gastrointestinal or genitourinary bleeding, intracranial neoplasm, aneurysm, as it can cause serious adverse effects. Intiflo 0.75mg/100ml Injection is known to cause bleeding problems. However, if you observe severe bleeding that cannot be controlled, it is advised to stop administering Intiflo 0.75mg/100ml Injection immediately. Hence, close monitoring of patients is needed for any bleeding conditions. Talk to your doctor before receiving Intiflo 0.75mg/100ml Injection if you had a recent severe injury or surgery due to the risk of severe bleeding problems. Before taking Intiflo 0.75mg/100ml Injection inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding due to serious foetal harm. Intiflo 0.75mg/100ml Injection is not recommended for children below 12 years of age as efficacy and safety have not been established. Talk to your doctor before receiving Intiflo 0.75mg/100ml Injection if you have/had a recent severe injury or surgery due to the risk of severe bleeding problems.

• ASPIRIN
• CELECOXIB
• TRAMADOL
• CLOPIDOGREL
• ENOXAPARIN
• RIVAROXABAN
• ENALAPRIL
• CAPTOPRIL
• NIFEDIPINE
• CILNIDIPINE
• ATENOLOL
• SOTALOL
• WARFARIN
• TIROFIBAN
• ABCIXIMAB

• Before administration of Intiflo 0.75mg/100ml Injection, a blood test for CBC, serum creatinine, platelet count, prothrombin time, ACT, and APTT should be done to check for any hemostatic abnormalities.
• If heparin is given, it is always important to check the patient for any bleeding conditions.

• Eat a diet rich in whole grains, vegetables, fruits, skinless poultry, fish, eggs, and low-fat dairy products.
• Avoid smoking and alcohol consumption.
• Maintain a healthy weight with proper diet and exercise.
• Managing stress with meditation, yoga, and massage.
• Avoid eating fried food, fast food, boxed food, canned food, and processed frozen meals.